• In March 2026, Crinetics Pharmaceuticals submitted a Marketing Authorization Application to Brazil’s ANVISA for PALSONIFY, an oral somatostatin receptor type 2 agonist for adult acromegaly, supported by 18 clinical trials including two Phase 3 studies that met all primary and secondary endpoints and showed favorable tolerability, biochemical control and symptom relief versus placebo.
• This filing extends PALSONIFY’s regulatory footprint beyond its existing US approval and recent positive CHMP opinion in Europe, underscoring Crinetics’ efforts to build a global acromegaly franchise while advancing paltusotine into Phase 3 development for carcinoid syndrome.
• Next, we’ll examine how this Brazil MAA for PALSONIFY, supported by extensive Phase 3 data, may influence Crinetics’ broader investment narrative.

This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.

Crinetics Pharmaceuticals Investment Narrative Recap

To own Crinetics, you need to believe PALSONIFY can become a meaningful oral standard in acromegaly while the broader endocrine pipeline matures, despite current losses and cash burn. The Brazil MAA builds on US and European progress but does not by itself change the near term focus on U.S. launch execution or the key risk that prescription uptake and payer access may fall short of expectations.

The recent resignation of Chief Development and Operating Officer Jeff Knight is the most relevant nearby event, given Crinetics’ dependence on complex, late stage programs like PALSONIFY and paltusotine in carcinoid syndrome. Management says responsibilities are being reassigned internally, but with multiple Phase 3 trials ongoing, any disruption to development or operational continuity could affect timelines and, in turn, the path to future revenue diversification.

However, investors should also be aware that if PALSONIFY uptake remains slower than hoped, the combination of heavy spending and the possibility of future dilution could...

Crinetics Pharmaceuticals' narrative projects $454.3 million revenue and $94.8 million earnings by 2029. This would require 566.4% yearly revenue growth and a roughly $518 million earnings increase from -$423.1 million today.

Uncover how Crinetics Pharmaceuticals' forecasts yield a $82.43 fair value, a 121% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenue could reach about US$534.2 million by 2028, yet this Brazil filing and the risk that trial or reimbursement hurdles could slow diversification show how far opinions can differ and why you may want to compare several viewpoints before deciding what you believe.

Explore 4 other fair value estimates on Crinetics Pharmaceuticals - why the stock might be a potential multi-bagger!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Crinetics Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Crinetics Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Crinetics Pharmaceuticals' overall financial health at a glance.

Seeking Other Investments?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.